Format
Sort by
Items per page

Send to

Choose Destination

Best matches for disease progression AND melanoma:

Maspin expression and melanoma progression: a matter of sub-cellular localization. Martinoli C et al. Mod Pathol. (2014)

Dysplastic nevi and melanoma. Goldstein AM et al. Cancer Epidemiol Biomarkers Prev. (2013)

Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Jordan KR et al. Cancer Immunol Immunother. (2013)

Search results

Items: 1 to 20 of 5341

1.

Early onset of diffuse melanosis cutis under pembrolizumab therapy illustrates the limitations of anti-PD-1 checkpoint inhibitors.

Thiem A, Schummer P, Ueberschaar S, Kerstan A, Kneitz H, Schrama D, Appenzeller S, Meierjohann S, Schilling B, Goebeler M, Gesierich A.

Melanoma Res. 2018 May 17. doi: 10.1097/CMR.0000000000000458. [Epub ahead of print]

PMID:
29781871
2.

Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma.

Bezrookove V, Nosrati M, Miller JR, de Semir D, Dar AA, Vosoughi E, Vaquero E, Sucker A, Lazar AJ, Gershenwald JE, Davies MA, Schadendorf D, Kashani-Sabet M.

Clin Cancer Res. 2018 May 18. pii: clincanres.0791.2018. doi: 10.1158/1078-0432.CCR-18-0791. [Epub ahead of print]

PMID:
29776954
3.

Erythema Nodosum as the Initial Presentation of Nivolumab-Induced Sarcoidosis-Like Reaction.

Laroche A, Alarcon Chinchilla E, Bourgeault E, Doré MA.

J Cutan Med Surg. 2018 May 1:1203475418776934. doi: 10.1177/1203475418776934. [Epub ahead of print]

PMID:
29772919
4.

Cutaneous Papillomaviruses and Non-melanoma Skin Cancer: Causal Agents or Innocent Bystanders?

Hasche D, Vinzón SE, Rösl F.

Front Microbiol. 2018 May 2;9:874. doi: 10.3389/fmicb.2018.00874. eCollection 2018. Review.

5.

Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases.

Filippou PS, Ren AH, Korbakis D, Dimitrakopoulos L, Soosaipillai A, Barak V, Frenkel S, Pe'er J, Lotem M, Merims S, Molina R, Blasutig I, Bogdanos DP, Diamandis EP.

Clin Chem Lab Med. 2018 May 16. pii: /j/cclm.ahead-of-print/cclm-2018-0139/cclm-2018-0139.xml. doi: 10.1515/cclm-2018-0139. [Epub ahead of print]

PMID:
29768245
6.

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series.

Sun L, Funchain P, Song JM, Rayman P, Tannenbaum C, Ko J, Mcnamara M, Marcela Diaz-Montero C, Gastman B.

J Immunother Cancer. 2018 May 16;6(1):36. doi: 10.1186/s40425-018-0337-7.

7.

Insights into the role of IL-32 in cancer.

Sloot YJE, Smit JW, Joosten LAB, Netea-Maier RT.

Semin Immunol. 2018 May 7. pii: S1044-5323(17)30079-9. doi: 10.1016/j.smim.2018.03.004. [Epub ahead of print] Review.

PMID:
29747940
8.

Circulating Tumor Cells in Stage IV Melanoma Patients.

Hall CS, Ross M, Bowman Bauldry JB, Upshaw J, Karhade MG, Royal R, Patel S, Lucci A.

J Am Coll Surg. 2018 May 7. pii: S1072-7515(18)30325-9. doi: 10.1016/j.jamcollsurg.2018.04.026. [Epub ahead of print]

PMID:
29746918
9.

Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer.

Cavalieri S, Perrone F, Miceli R, Ascierto PA, Locati LD, Bergamini C, Granata R, Alfieri S, Resteghini C, Galbiati D, Busico A, Paielli N, Patuzzo R, Maurichi A, Gallino G, Ruggeri R, Mariani L, Palla M, Licitra L, Bossi P.

Eur J Cancer. 2018 May 4;97:7-15. doi: 10.1016/j.ejca.2018.04.004. [Epub ahead of print]

PMID:
29734047
10.

Medication use evaluation of programmed death-1 inhibitors in a veteran population.

Nguyen V, Huq M.

J Oncol Pharm Pract. 2018 Jan 1:1078155218772654. doi: 10.1177/1078155218772654. [Epub ahead of print]

PMID:
29726785
11.

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors.

Faure M, Rochigneux P, Olive D, Taix S, Brenot-Rossi I, Gilabert M.

Front Immunol. 2018 Apr 19;9:797. doi: 10.3389/fimmu.2018.00797. eCollection 2018.

12.

Vemurafenib in Chinese patients with BRAF<sup>V600</sup> mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.

Si L, Zhang X, Xu Z, Jiang Q, Bu L, Wang X, Mao L, Zhang W, Richie N, Guo J.

BMC Cancer. 2018 May 3;18(1):520. doi: 10.1186/s12885-018-4336-3.

13.

Outcomes following therapeutic lymphadenectomy for Stage III malignant melanoma in a single unit.

Jayakar R, Yassaie E, Adams C.

N Z Med J. 2018 May 4;131(1474):51-59.

PMID:
29723179
14.

Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab.

Kverneland AH, Enevold C, Donia M, Bastholt L, Svane IM, Nielsen CH.

Oncoimmunology. 2018 Feb 1;7(5):e1424674. doi: 10.1080/2162402X.2018.1424674. eCollection 2018.

15.

Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma.

Audrito V, Managò A, Zamporlini F, Rulli E, Gaudino F, Madonna G, D'Atri S, Antonini Cappellini GC, Ascierto PA, Massi D, Raffaelli N, Mandalà M, Deaglio S.

Oncotarget. 2018 Apr 10;9(27):18997-19005. doi: 10.18632/oncotarget.24871. eCollection 2018 Apr 10.

16.

Blood neutrophil-to-lymphocyte ratio is associated with prognosis in advanced gastrointestinal stromal tumors treated with imatinib.

Rutkowski P, Teterycz P, Klimczak A, Bylina E, Szamotulska K, Lugowska I.

Tumori. 2018 Apr 1:300891618765543. doi: 10.1177/0300891618765543. [Epub ahead of print]

PMID:
29714669
17.

Are Anti-Retinal Autoantibodies a Cause or a Consequence of Retinal Degeneration in Autoimmune Retinopathies?

Adamus G.

Front Immunol. 2018 Apr 16;9:765. doi: 10.3389/fimmu.2018.00765. eCollection 2018. Review.

18.

Enhanced intratumoral expression of RNF2 is a favorable prognostic factor for patients with cutaneous melanoma?

Kuźbicki Ł, Lange D, Stanek-Widera A, Glińska A, Chwirot BW.

Oncotarget. 2018 Apr 3;9(25):17656-17663. doi: 10.18632/oncotarget.24825. eCollection 2018 Apr 3.

19.

Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies.

Brastianos PK, Ippen FM, Hafeez U, Gan HK.

Oncologist. 2018 Apr 27. pii: theoncologist.2017-0614. doi: 10.1634/theoncologist.2017-0614. [Epub ahead of print] Review.

PMID:
29703764
20.

Circulating MicroRNA Biomarkers in Melanoma: Tools and Challenges in Personalised Medicine.

Mumford SL, Towler BP, Pashler AL, Gilleard O, Martin Y, Newbury SF.

Biomolecules. 2018 Apr 26;8(2). pii: E21. doi: 10.3390/biom8020021. Review.

Supplemental Content

Loading ...
Support Center